张士舜三辨论治理论治疗晚期肺癌临床疗效分析
|
摘要
目的:运用张士舜三辨论治理论治疗晚期肺癌疗效观察。方法:122例肺癌晚期患者,其中鳞癌44例,腺癌40例,小细胞癌33例,其它5例,均有病理诊断。自开始应用三辨论治理论治疗后未再行手术、放疗及化疗,对照组采用刘嘉湘期刊发表的运用辨证论治治疗原发性肺癌及冉文华期刊发表的放化疗后中药维持治疗广泛期小细胞肺癌的临床观察研究。结果:三辨论治治疗原发性肺癌治疗组与中医运用辨证论治治疗原发性肺癌对照组1、2、3、4、5年生存率及中位生存期分别为86.89%和43.23%、50.82%和11.29%、27.87%和5.16%、14.75%和1.61%、10.66%和0.64%、24个月和11.2个月,其中鳞癌治疗组与对照组1、2、3年生存率及中位生存期分别为90.91%和45%、50.00%和11.8%、20.45%和7%、23.5个月和11.2个月,其中腺癌治疗组与对照组1、2、3年生存率及中位生存期分别为92.5%和35.94%、52.50%和11%、35.00%和4.6%、24个月和11.2个月。三辨论治治疗非小细胞肺癌与益肺抗瘤饮治疗非小细胞肺癌对照组1、2、3、4年生存率及中位生存期分别为92.13%和73.09%、52.81%和32.01%、26.97%和13.18%、15.73%和13.18%、24个月和13.2个月。三辨论治治疗广泛期小细胞肺癌治疗组与放化疗后中药维持治疗广泛期小细胞肺癌的临床观察研究对照组1、2、3、5年生存率及中位生存期分别为72.73%和38.6%、45.45%和18.1%、30.30%和13.6%、9.09%和6.8%、18个月和11.1个月。结论:三辨论治理论治疗晚期肺癌较单纯辨证论治治疗晚期肺癌明显提高患者的生存率,延长生存期,同时也为研究肺癌新药奠定了基础。
Objective:To observe the curative effect of using ZHANG Shishun's theory that treatment based on three differentiation to treat advanced lung cancer. Methods:In this paper,122 cases with advanced lung cancer who did not undergo surgery,radiotherapy or chemotherapy any longer after being treated by using this theory were randomly selected as our research objects,including 44 cases of lung squamous cell carcinoma,40 cases of lung adenocarcinoma,33 cases of small cell carcinoma of lung and 5 others. The results from the clinical research on the curative effect of using treatment based on syndrome differentiation to treat non-small cell conducted by Professor LIU Jiaxiang and the results from the clinical research of extensive stage small cell lung cancer treated by Chinese medicine after chemoradiotherapy conducted by Professor RAN Wenhua were chosen as the control groups. Results:Comparing the treatment group of primary lung cancer and control group of primary lung cancer,the survival rate of one year,two years,three years,four years and five years of the two groups were 86.89% and 43.23%,50.82% and 11.29%,27.87% and 5.16%,14.75% and 1.61%,10.66% and 0.64%,respectively,and the median survival times of the two group were 24 months and 11.2 months,respectively. Among them,the survival rate of one year,two years and three years was 90.91%,50.00% and 20.45% in treatment group of squamous cell carcinoma and 45%,11.8% and 7% in control group,and the median survival time was 23.5 months in treatment group and 11.2 months in control group. The survival rate of one year,two years and three years was 92.5%,52.50% and 35.00% in treatment group of adenocarcinoma and 35.94%,11% and 4.6% in control group,and the median survival time was 24 months in treatment group and 11.2 months in control group. The survival rate of one year,two years,three years and four years was 92.13%,52.81%,26.97% and 15.73% in treatment group of non-small cell lung cancer and 73.09%,32.01%,13.18% and 13.18% in control group of non-small cell lung cancer,and the median survival time was 24 months in treatment group and 13.2 months in control group. The survival rate of one year,two years,three years and five years was 72.73%,45.45%,30.3% and9.09% in treatment group of small cell carcinoma and 38.6%,18.1%,13.6% and 6.8% in control group,and the median survival time was 18 months in treatment group and 11.1 months in control group. Conclusion:Compared with the treatment of simple syndrome differentiation,the treatment based on three differentiation can significantly increase the survival time of patients,which establishes stable foundation for developing new drugs to treat lung cancer.
Objective:To observe the curative effect of using ZHANG Shishun's theory that treatment based on three differentiation to treat advanced lung cancer. Methods:In this paper,122 cases with advanced lung cancer who did not undergo surgery,radiotherapy or chemotherapy any longer after being treated by using this theory were randomly selected as our research objects,including 44 cases of lung squamous cell carcinoma,40 cases of lung adenocarcinoma,33 cases of small cell carcinoma of lung and 5 others. The results from the clinical research on the curative effect of using treatment based on syndrome differentiation to treat non-small cell conducted by Professor LIU Jiaxiang and the results from the clinical research of extensive stage small cell lung cancer treated by Chinese medicine after chemoradiotherapy conducted by Professor RAN Wenhua were chosen as the control groups. Results:Comparing the treatment group of primary lung cancer and control group of primary lung cancer,the survival rate of one year,two years,three years,four years and five years of the two groups were 86.89% and 43.23%,50.82% and 11.29%,27.87% and 5.16%,14.75% and 1.61%,10.66% and 0.64%,respectively,and the median survival times of the two group were 24 months and 11.2 months,respectively. Among them,the survival rate of one year,two years and three years was 90.91%,50.00% and 20.45% in treatment group of squamous cell carcinoma and 45%,11.8% and 7% in control group,and the median survival time was 23.5 months in treatment group and 11.2 months in control group. The survival rate of one year,two years and three years was 92.5%,52.50% and 35.00% in treatment group of adenocarcinoma and 35.94%,11% and 4.6% in control group,and the median survival time was 24 months in treatment group and 11.2 months in control group. The survival rate of one year,two years,three years and four years was 92.13%,52.81%,26.97% and 15.73% in treatment group of non-small cell lung cancer and 73.09%,32.01%,13.18% and 13.18% in control group of non-small cell lung cancer,and the median survival time was 24 months in treatment group and 13.2 months in control group. The survival rate of one year,two years,three years and five years was 72.73%,45.45%,30.3% and9.09% in treatment group of small cell carcinoma and 38.6%,18.1%,13.6% and 6.8% in control group,and the median survival time was 18 months in treatment group and 11.1 months in control group. Conclusion:Compared with the treatment of simple syndrome differentiation,the treatment based on three differentiation can significantly increase the survival time of patients,which establishes stable foundation for developing new drugs to treat lung cancer.
引文
[1]Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
[2]Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CACancer J Clin,2011,61(2):69-90.
[3]Ferlay J,Shin HR,Bray F,et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer,2010,127(12):2893-2917.
[4]陈万青,张思维,郑荣寿,等.中国肿瘤登记地区2007年肿瘤发病和死亡分析[J].中国肿瘤,2011,20(3):162-169.
[5]刘嘉湘.现代中医药应用与研究大系·肿瘤科[M].上海:上海中医药大学出版社,1996:130.
[6]刘嘉湘.辨证治疗原发性肺癌310例疗效分析[J].上海中医药杂志,1985(10):3-6.
[7]刘嘉湘.肺癌的中医药治疗进展[J].中国肿瘤,2002,11(6):326-329.
[8]刘嘉湘,施志明,李和根,等.益肺抗瘤饮治疗271例非小细胞肺癌临床观察[J].上海中医药杂志,2001(2):4-6.
[9]冉文华.放化疗后中药维持治疗广泛期小细胞肺癌的临床研究[J].重庆医科大学学报,2011,36(3):356-358.
[10]张士舜.三辨治癌[N].中国中医药报,2004-04-19.
[2]Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CACancer J Clin,2011,61(2):69-90.
[3]Ferlay J,Shin HR,Bray F,et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer,2010,127(12):2893-2917.
[4]陈万青,张思维,郑荣寿,等.中国肿瘤登记地区2007年肿瘤发病和死亡分析[J].中国肿瘤,2011,20(3):162-169.
[5]刘嘉湘.现代中医药应用与研究大系·肿瘤科[M].上海:上海中医药大学出版社,1996:130.
[6]刘嘉湘.辨证治疗原发性肺癌310例疗效分析[J].上海中医药杂志,1985(10):3-6.
[7]刘嘉湘.肺癌的中医药治疗进展[J].中国肿瘤,2002,11(6):326-329.
[8]刘嘉湘,施志明,李和根,等.益肺抗瘤饮治疗271例非小细胞肺癌临床观察[J].上海中医药杂志,2001(2):4-6.
[9]冉文华.放化疗后中药维持治疗广泛期小细胞肺癌的临床研究[J].重庆医科大学学报,2011,36(3):356-358.
[10]张士舜.三辨治癌[N].中国中医药报,2004-04-19.